چكيده لاتين :
Background: The negative symptoms of schizophrenia remain
a major clinical challenge. Nortriptyline is a serotonin
and noradrenalin reuptake inhibitor and belongs to secondary
amine tricycles. The aim of this study is to evaluate the effect
of nortriptyline on the negative symptoms of schizophrenia.
Methods: This study is a six-week randomized placebocontrol
trial of nortriptyline or placebo as an adjunctive to
haloperidol (5 mg) in the treatment of 50 patients with Diagnostic
and statistical manual for Mental Disorders (DSM-IV)
criteria for chronic schizophrenia.
Result: The primary finding of the trial was a significant reduction
in Scale for Assessment of Negative Symptoms
(SANS) in the nortriptyline group compared to placebo at the
end of 6 week, All the subscales of SANS demonstrate significant
improvement.
Conclusion: This study suggests a potential role for nortriptyline
in the treatment of negative symptoms of schizophrenia.
